Nicox published a third quarter operational update on 19 October and provided new prescriptions uptake data for its two commercial-stage out-licensed products, Vyzulta and Zerviate. Nicox reported that the number of US prescriptions for Vyzulta rose by 35% y-o-y in Q321 and for Zerviate the increase was 213% y-o-y. Net royalties increased by c €0.1m q-o-q to €0.7m. The company also reiterated recent guidance on the progress of its key internal programmes, including the reporting of primary efficacy data for the Mont Blanc NCX-470 Phase III study in Q123.
26 Oct 2021
Nicox - Commercial products continue to grow
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Nicox - Commercial products continue to grow
- Published:
26 Oct 2021 -
Author:
Pooya Hemami -
Pages:
6
Nicox published a third quarter operational update on 19 October and provided new prescriptions uptake data for its two commercial-stage out-licensed products, Vyzulta and Zerviate. Nicox reported that the number of US prescriptions for Vyzulta rose by 35% y-o-y in Q321 and for Zerviate the increase was 213% y-o-y. Net royalties increased by c €0.1m q-o-q to €0.7m. The company also reiterated recent guidance on the progress of its key internal programmes, including the reporting of primary efficacy data for the Mont Blanc NCX-470 Phase III study in Q123.